Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 3 1Phase 2/3 1

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 2Melanoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × soluble LAG-3 protein, human × Clear all
NCT04252768 2023-03-22

AIPAC-002

Immutep S.A.S.

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT02676869 2019-12-18

TACTI-mel

Immutep Australia Pty. Ltd.

Phase 1 Completed
24 enrolled
Dermatologic

Melanoma

NCT00349934 2010-01-07

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Immutep S.A.S.

Phase 1 Completed
33 enrolled
Breast

Breast Neoplasms

NCT00351949 2010-01-07

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Immutep S.A.S.

Phase 1 Completed
24 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡